Test strip and method for detecting urine A beta amyloid protein

Abstract

The invention discloses a test strip and method for detecting urine A beta amyloid protein. The test strip for detecting the urine A beta amyloid protein comprises a PVC bottom plate (7), wherein a sample pad (1), a conjugated pad (2), a chromatography pad (3) and a water absorption pad (4) which are sequentially overlapped are paved on the PVC bottom plate (7); the conjugated pad (2) is coated with colloidal gold particles conjugated with a monoclonal antibody; a detection line (5) is arranged on one side, close to the conjugated pad (2), of the chromatography pad (3); a contrast control line(6) is arranged on one side, close to the water absorption pad (4), of the chromatography pad (3); the detection line (5) is coated with an A beta amyloid protein binding polymer; and the contrast control line (6) is coated with a goat anti-mouse IgG polyclonal antibody. The method is high in sensitivity, has a detection limit of 40 pg, is rapid and economical, is suitable for conventional clinical pathological examination, is suitable for general screening of a large number of people and self-screening of home terminal users, is especially used for clinically assisting early diagnosis and pre-judgment of mild cognitive impairment (MCI), and predicts and judges whether a patient has high risk of developing MCI and AD.

Description

technical field [0001] The invention relates to a test strip and a method for detecting urine Aβ amyloid protein. Background technique [0002] Alzheimer's disease (AD) is the most common form of dementia, affecting more than 26 million people worldwide. We and others have found that a large proportion (30%) of cognitively normal older adults exhibit high retention of PET ligands in the brain and low levels of Aβ in the cerebrospinal fluid (CSF) 1-42 , these individuals are currently diagnosed with Alzheimer's disease in the preclinical latent stage. Mild cognitive impairment (MCI) is considered a prodromal stage of AD, and 40-60% of patients meeting MCI criteria will eventually develop clinical AD, accounting for about 5-25% per year. The main etiology of sporadic AD is the accumulation of Aβ and the failure of Aβ clearance. At present, the "amyloid cascade hypothesis" is generally supported in this research field, that is, the metabolic imbalance of Aβ in the brain is t...

AI Technical Summary

Problems solved by technology

The target antigen is too small, only 4.3kD, and is prone to non-specific binding with other proteins, so it is difficult to achieve high sensitivity and specificity by the commonly used "double antibody sandwich method" or "competition method"

Images